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RECOMENDACIONES DEL GRUPO GARIN
PARA EL MANEJO DE PACIENTES NO CRÍTICOS
CON DIABETES O HIPERGLUCEMIA DE ESTRÉS
Y NUTRICIÓN ARTIFICIAL
Resumen
Introducción y objetivos: En el tratamiento de los
pacientes con diabetes o hiperglucemia de estrés y la
nutrición artificial existen muchas áreas de incertidum-
bre, sobre todo en pacientes no críticos. El grupo de tra-
bajo GARIN tiene como objetivo definir su posición en
este campo. 
Material y métodos: Revisión bibliográfica previa y
reunión presencial en la que se discutieron y contestaron
preguntas específicas sobre el tema.
Resultados: Proponemos una definición de hipergluce-
mia de estrés. Las indicaciones y las rutas de acceso a la
nutrición artificial no difieren en los pacientes con hiper-
glucemia de estrés o diabetes respecto a los no diabéticos.
El objetivo debe ser mantener los niveles de glucemia pre-
prandial entre 100 y 140 mg/dl y postprandial entre 140 y
180 mg/dl. La hiperglucemia puede prevenirse a través de
una monitorización sistemática de las glucemias capilares
y un cálculo adecuado de las necesidades energético-pro-
teicas. 
Recomendamos el uso de fórmulas enterales diseñadas
para pacientes con diabetes (alto contenido en grasas
monoinsaturadas) para facilitar el control metabólico. El
mejor tratamiento farmacológico para tratar la hiperglu-
cemia/diabetes en pacientes hospitalizados es la insulina,
aconsejando adaptar la acción teórica de la insulina al
régimen de infusión de la nutrición. También realizamos
recomendaciones para investigaciones futuras. 
Conclusiones: Estas recomendaciones aportan res-
puestas concretas sobre cuestiones comunes en la asisten-
cia a pacientes con diabetes o hiperglucemia de estrés y
nutrición artificial. 
(Nutr Hosp. 2012;27:1837-1849)
DOI:10.3305/nh.2012.27.6.6076
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Abstract
Background & aims: By means of this update, the
GARIN working group aims to define its position
regarding the treatment of patients with diabetes or stress
hyperglycaemia and artificial nutrition. In this area there
are many aspects of uncertainty, especially in non-criti-
cally ill patients.
Methods: Bibliographical review, and specific ques-
tions in advance were discussed and answered at a
meeting in the form of conclusions. 
Results: We propose a definition of stress hypergly-
caemia. The indications and access routes for artificial
nutrition are no different in patients with diabetes/stress
hyperglycaemia than in non-diabetics. The objective
must be to keep pre-prandial blood glucose levels
between 100 and 140 mg/dl and post-prandial levels
between 140 and 180 mg/dl. Hyperglycemia can be
prevented through systematic monitoring of capillary
glycaemias and adequately calculate energy-protein
needs. We recommend using enteral formulas designed
for patients with diabetes (high monounsaturated fat) to
facilitate metabolic control. The best drug treatment for
treating hyperglycaemia/diabetes in hospitalised patients
is insulin and we make recommendations for adapt the
theoretical insulin action to the nutrition infusion
regimen. We also addressed recommendations for future
investigation.
Conclusions: This recommendations about artificial
nutrition in patients with diabetes or stress hypergly-
caemia can add value to clinical work.
(Nutr Hosp. 2012;27:1837-1849)
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Introduction 
Although dietary recommendations have formed
part of medicine for many centuries, nutrition has only
been considered a scientific discipline for about 200
years, initially starting alongside advances in chem-
istry when early experiments into nutrient oxidation
were conducted.1 However, the “clinical nutrition”
discipline did not emerge until the end of the 1960s
when it was proven to be possible to maintain the
growth and life of a child by exclusively administering
nutrients parenterally.2 Today, clinical nutrition is a
multi-disciplinary area that supports most medical
specialties and has come of age by incorporating scien-
tific methodology and evidence-based medicine to
establish clinical practice guidelines.3,4
Nevertheless, there are still many areas of uncertainty
due to it being a relatively young specialty and it being
difficult to conduct well-designed studies (observational
and/or randomised, prospective clinical trials with a
sufficient number of patients) allowing conclusions
based on the best available evidence to be reached.
One of these areas is artificial nutrition in patients
with diabetes or stress hyperglycaemia in which there
are many aspects still requiring clarification, especially
in non-critically ill patients. In fact, the latest clinical
practice guidelines on the management of hypergly-
caemia in non-critical hospitalised patients, published
by the U.S. Endocrine Society5 and the American
Society for Parenteral and Enteral Nutrition (ASPEN),6
only make three evidence-based recommendations on
general aspects of care for patients receiving artificial
nutrition (enteral or parenteral), which shows the high
degree of uncertainty faced by clinicians; the first one5
also only makes one strong recommendation based in
high quality evidence and two weak recommendations
based on very low quality evidence and the second one6
two strong recommendations and it cannot make a
recommendation about the third question because of
lack of evidence. Also the recent clinical practice
guidelines published by the American College of
Physicians about use of Intensive Insulin Therapy for
the Management of Glycemic Control in Hospitalized
Patients only makes three recommendations focused
on critical patients; the two strong recommendations
are about not using intensive insulin therapy and the
weaker recommends a target blood glucose level if
insulin therapy is used.7 Also the recent consensus of
SEMICYUC-SENPE makes recommendations only
centered in critically ill patients.8
Therefore, in fields with high levels of uncertainty
and low quality evidence, expert consensus or recom-
mendations can add value to clinical work. 
By means of this revision and update, the GARIN
(Grupo Andaluz de Reflexión e Investigación en Nutri-
ción) working group aims to define its position
regarding the treatment of patients with diabetes and
artificial nutrition based on the critical reading of liter-
ature and also the experience of group members. 
Material and methods 
The main objectives of the GARIN group include
reflecting on various aspects of clinical nutrition and
generating recommendations agreed by consensus. Its
members meet once a year in Osuna (Andalusia, Spain)
after first systematically reviewing the best available
evidence on a pre-agreed specific topic. Initially, a
bibliographical review is carried out of the papers
published on PubMed regarding enteral nutrition,
parenteral nutrition and hyperglycaemia or diabetes:
all members review this literature prior to the meeting
(two months in advance). The topic was formally
presented by the coordinator at the meeting for 45
minutes and then a series of specific questions that
were written by the coordinator (GO) in advance (of
which all were pre-informed) were discussed for the
next four hours. These were answered at the meeting in
the form of conclusions. The review of the literature
and the answers to these questions are reflected in this
article, which has been prepared by the coordinator and
then discussed and adopted by all participants. 
Review of the literature 
Prevalence of diabetes mellitus and hyperglycemia 
in hospitalised patients receiving artificial nutrition
It is estimated that there are currently 246 million
people with diabetes in the world and that this figure
will increase over the next few years, reaching 380
million by the year 2025 according to the latest predic-
tions.9 An ageing population and lifestyle-related
factors (changes in diet and increased sedentary
lifestyle with consequent weight gain and obesity) are
the main factors behind this epidemic.10,11
It is estimated that around 14% of the adult popula-
tion in Spain has diabetes.12,13 The prevalence of
diabetes in the hospital setting is also very high, at
about 11%, if data are taken from the administrative
databases generated from hospital discharge reports,13-15
exceeding 21% in the subgroup of patients over the age
of 75 years.14 However, if data are taken from hospital
medical charts or prospective studies, the prevalence is
higher still, at around 20-30%, while in patients over
the age of 65 years or patients admitted to certain
departments such as cardiology or cardiovascular
surgery, the prevalence is even higher than 30%.16-18
The presence of diabetes in hospitalised patients is
associated with an increased risk of death during hospi-
talisation, an increased length of hospital stay (3-4 days
on average) and increased costs.14,15,19
Stress hyperglycaemia (in patients without diabetes)
associated with acute diseases also seems to increase
the morbidity and mortality of hospitalised patients 20.
Nevertheless, there are no reliable data regarding the
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prevalence of this disorder as different definitions are
given in the literature and none are accepted interna-
tionally.21-23
It is estimated that 8% of hospitalised patients
receive some type of artificial enteral feeding support
to treat or prevent malnutrition, whether as supple-
ments or complete diets.24,25 Approximately 2-3% more
receives total parenteral nutritional support (TPN) for
the same purpose. 
Hyperglycaemia is a common complication in
hospitalised patients receiving enteral nutrition.26,27
Nevertheless, the prevalence of diabetes in patients
receiving enteral nutrition is unknown. In one study
involving an internal medicine department, 34% of
patients receiving TEN had blood glucose levels over
200 mg/dl.28 In another study assessing dependent geri-
atric patients (with severe cognitive impairment)
admitted to long-term care units and receiving enteral
nutrition, 50% had diabetes (defined as an HbA1C
above 7%) with 44% of them being undiagnosed.29 In a
randomised study comparing two insulin therapy regi-
mens in patients with enteral nutrition and diabetes
(defined as two blood glucose levels above 130 mg/dl),
half of the 50 randomised patients did not know they
had diabetes.30
Between 16 and 30% of the subjects randomised to
intervention trials comparing intensive and conventional
insulin treatment in critically ill patients had diabetes
mellitus prior to randomisation.31-36 Nevertheless, the
prevalence of hyperglycaemia or previously diagnosed
diabetes in patients receiving TPN treatment, especially
in patients from non-critically ill units, has not been well
studied. In a series of 50 retrospective cases, Pleva et al.
describe rates of hyperglycaemia above 150 mg/dl in
more than 90% of patients receiving TPN.37 Among
hospitalised patients receiving TPN in Spain from
general wards (not intensive care units), prevalences of
hyperglycaemia above 200 mg/dl have been described in
12-27% of patients.38,39 In a recent study conducted by the
Group for the Study of Hyperglycaemia during
Parenteral Nutrition of the Area of Nutrition of the
Sociedad Española de Endocrinología y Nutrición
(Spanish Society of Endocrinology and Nutrition),40 51%
of patients (non-critically ill) prescribed TPN had some
type of glucose metabolism alteration prior to starting
TPN (based on blood glucose and glycated haemoglobin
values): known diabetes 18%, undiagnosed diabetes
3.8%, stress hyperglycaemia 12.4%, being at risk for the
development of diabetes 15%. During the TPN infusion,
80% of patients had at least one capillary blood glucose
measurement above 140mg/dl with 51% above 180
mg/dl. 
Effects of hyperglycaemia on the outcome 
of hospitalised patients 
Short-term hyperglycaemia in hospitalised patients
has been related to an increased susceptibility to infec-
tions and other alterations, such as increased oxidative
stress, increased hypercoagulability, dyslipidemia,
etc., resulting in a secondary increase in morbidity,
mortality and generated costs.25 This increase in
complications and mortality has been observed with
different clinical conditions (myocardial infarction,
strokes, trauma, coronary bypass, COPD, elderly
patients, etc.).41 
Experimental data are currently available on poten-
tial mechanisms from observational and intervention
clinical studies that support the fact that hypergly-
caemia per se, in addition to being a marker of illness
severity, causes major adverse effects that affect the
prognosis of hospitalised patients, including increased
mortality, rates of infection and length of hospital stay.
Some studies also suggest that stricter control of blood
glucose levels in critically ill patients with and without
diabetes could improve their prognosis.5,18,26,42 
In the case of patients receiving TPN (both in criti-
cally ill and non-critically ill patients), it seems that
hyperglycaemia per se, possibly independently of the
previous presence of diabetes, could worsen the prog-
nosis of patients by increasing morbidity and mortality
(increased cardiac, infectious and septic complica-
tions, renal failure, etc.), especially if not associated
with insulin therapy.26,43-49
Objectives of hyperglycaemia treatment 
in non-critically ill patients 
Until the beginning of the 21st century, it was gener-
ally accepted that blood glucose levels of hospitalised
patients should be kept within safe limits between 150
and 250 mg/dl. However, following the first papers
published by the Van den Berghe group in ICU
patients,36 this concept was rethought and substituted by
another concept supporting a more active approach in
order to achieve better glycaemic control. Therefore,
over recent years, the management of hyperglycaemia
during hospitalisation has become particularly relevant
with recommendations being established that suggest
that the objective of glycaemic control during hospitali-
sation should be to normalise blood glucose levels.18,26,42
Nevertheless, the treatment of hyperglycaemia with
the objective of normalising blood glucose levels has
had contradictory results in the literature, especially in
critically ill patients, the area where most randomised
and controlled trials have been conducted. Therefore,
studies by Van den Berghe in critically ill patients
showed a reduction in mortality in surgical patients
assigned to intensive IV insulin treatment (objective
80-110 mg/dl) compared to conventional treatment
(starting infusion with blood glucose levels above 220
mg/dl with the objective of 180-200 mg/dl).36 The same
group managed to replicate results (lower mortality) in
critically ill patients in ICUs, but only in those patients
receiving treatment for more than 3 days.35 However,
other randomised, multi-centre studies in critically ill
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patients comparing intensive and conventional treat-
ment (generally with stricter control in the conven-
tional group than in studies conducted by Van den
Berghe) have not been able to replicate the same results
(no reduction in mortality has been observed and in
some cases an increase in mortality has even been
noted, possibly related to hypoglycaemia).31-34
Although there is a huge debate in the literature41,48,50-52
regarding the disparity between results in the different
papers on intensive treatment, part of the effects could
be due to the nutritional therapy used in the different
studies (higher parenteral infusion rate of glucose and
nutrients in the Van den Berghe studies compared to
the others).
In a recent systematic review and meta-analysis on
the use of intensive insulin therapy (with an approxi-
mate treatment objective of 140-180 mg/dl) in non-
critically ill patients, a reduced risk of infections and a
tendency towards a higher incidence of hypoglycaemia
compared to patients treated with conventional insulin
therapy was observed.53
After initially adopting the objective of normogly-
caemia, clinical practice guidelines and consensus
currently recommend maintaining a pre-prandial
glucose level of less than 140 mg/dl and a glucose level
of 180 mg/dl at all other times in most “non-critically
ill” patients.5,18 Objectives may vary based on the clin-
ical situation (with objectives being less strict, for
example, in patients with a short vital prognosis or a
high risk of hypoglycaemia).
Indications for artificial nutrition 
in patients with diabetes 
Indications for artificial nutritional support in patients
with diabetes are no different from those for patients
without diabetes. Enteral nutrition is indicated in those
patients that cannot, should not or do not want to meet
adequate nutritional requirements by oral intake and who
have a functioning, accessible gastrointestinal tract.
Between 5 and 8% of hospitalised patients receive
some type of artificial enteral feeding support, either as
supplements or complete diets.25 If we apply the actual
hospital diabetes prevalence rates, we can estimate that
1-2% of hospitalised patients are diabetic and receive
some type of enteral artificial nutritional support. 
The prescription of home enteral nutrition (HEN) is
also gradually increasing.54 The main indications for the
use of HEN54,55 are neurological alterations preventing
swallowing and neoplasms, which are more common
conditions in adults of advanced age. This means that
the prevalence of diabetes in patients prescribed home
enteral nutrition is potentially very high. 
TPN is prescribed to approximately 1-3% of hospi-
talised patients (based on their complexity) and has
proven to be effective and safe for restoring or main-
taining the nutritional status of patients who cannot
ingest or tolerate food via the digestive tract.56
However, as mentioned above, both parenteral and
enteral nutrition increase the risk of hyperglycaemia
regardless of the previously diagnosed presence of
diabetes28,40,44,49,57 and therefore strategies should be
implemented to prevent deleterious effects on the
outcome of patients, including the prevention and
adequate treatment of this complication. 
Treatment of hyperglycaemia/diabetes 
and enteral nutrition 
Selection of enteral formulas 
in diabetes/hyperglycaemia 
“Standard” commercial formulas used in enteral
nutrition have a high carbohydrate content (about
50%), a low-moderate lipid content (about 30%) and
contain no dietary fibre. These liquid formulations
seem to increase the glycaemic and insulin response
more in healthy people or patients with diabetes
mellitus when compared with a similar intake of nutri-
ents from a mixed meal. Although any formula can be
used in patients with diabetes, adjusting the insulin
therapy as required, enteral formulas designed specifi-
cally for patients with diabetes and stress hypergly-
caemia have been marketed over recent years to reduce
glycaemic response and also improve lipid profile and
other cardiovascular risk factors.25
All formulas “for diabetes” contain sources of
carbohydrates with a low glycaemic index, such as
non-hydrolysed starch or modified maltodextrin.
Although the addition of fructose is currently a matter
of debate, most add this nutrient in moderate-low
amounts. Likewise, all diabetic formulas add fibre,
almost always with a high proportion or exclusive
content of fermentable (“soluble”) fibre, which is asso-
ciated with an improved glucose and lipid profile.58-62
Also, most diabetes-specific enteral formulas have
increased the percentage of fat (preferably monounsat-
urated) compared to carbohydrates. In general, post-
prandial glycaemic response with a high intake of a
formula with a high monounsaturated fat content is
lower compared to formulas with a high carbohydrate
content as response depends fundamentally on the total
carbohydrate content. As the carbohydrate content of
the formulas increases, other factors also affect
glycaemic response, such as the carbohydrate source or
content and the type of fibre.58,60,62-64
Diabetes and stress diabetes-specific diets (especially
those high in fats) in hospitalised patients (in intensive
care or on general wards) reduce blood glucose levels and
insulin requirements without modifying aspects such as
hospital stay, infectious morbidity or mortality.65,66
High-fat diets also do not worsen lipid control and even
tend to improve it67 compared to high-carbohydrate
diets. The use of a diabetes-specific supplement in
outpatients, high in fat when compared to a hyperpro-
tein supplement, reduced medium-term glycaemic
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control (HbA1C).68 Short and medium-term (up to three
months) high-fat diabetes-specific diets in tube-fed
outpatients also improve metabolic control (blood
glucose levels, HbA1C and insulin requirements in
some cases) compared to standard formulas (generally
with fibre), although they do not modify morbidity.69-73
These formulas may also reduce glycaemic variability
and hypoglycaemia compared to standard formulas, at
least in the short term.71,73-75
To summarise, it must be highlighted that diets
designed for people with diabetes and stress hypergly-
caemia (especially those high in monounsaturated fats)
are safe and clearly reduce post-prandial blood glucose
levels, insulin requirements and, according to some
papers, glycaemic variability and medium-term HbA1C
without worsening or maybe even improving the lipid
profile. 
Nevertheless, more randomised and preferably
double-blind studies must be conducted that involve
more patients, lower rates of withdrawal from the
protocol and a longer duration in different clinical situ-
ations to assess the efficacy and efficiency (cost/effec-
tiveness) of such diets on metabolic effect and
morbidity and mortality in order to be able to give
better evidence-based recommendations.
In fact, although there are meta-analysis supporting
its use,62 the recent ASPEN guidelines conclude that
there aren’t sufficient data to recommend the use of
these formulas in hospitalized adult patients with
hyperglycemia.6
Treatment of hyperglycaemia in patients with
diabetes/stress hyperglycaemia and enteral nutrition 
To date, only one prospective randomised study has
been published that evaluates different insulin therapy
regimens in this type of patient.30 Korytkoswski et al.
studied 50 patients, 25 randomised to receive treatment
with insulin glargine and regular insulin compared to
25 randomised to sliding-scale insulin with added NPH
insulin if poor control persisted. Both strategies
showed a similar efficacy and safety in non-critically
ill patients receiving enteral nutrition. Half of the
patients in the sliding-scale group required added NPH
insulin. 
Other retrospective studies with a small number of
patients have shown the efficacy of the injection of
basal-bolus insulin regimens (insulin glargine + rapid-
acting insulin), 70% NPH and 30% rapid-acting insulin
biphasic insulin mixes (divided into 2 or 3 doses) and
NPH insulin sliding-scale regimens (divided into 4-6
doses) in patients receiving continuous enteral nutri-
tion with diabetes.76,77,78 Although conclusions cannot
easily be generalised (due to being retrospective
studies with few patients), it seems that the biphasic
insulin regimen in three doses or the NPH insulin
sliding-scale regimen (four daily injections) could be
advantageous for achieving better therapeutic objec-
tives, thus reducing hypoglycaemia. The use of insulin
glargine + insulin lispro in patients receiving enteral
nutrition in boluses also seems to be effective at
controlling hyperglycaemia.79
The percentage of hypoglycaemia in most studies
conducted with enteral nutrition and insulin therapy
varies between 3 and 5%, which is slightly higher than
the percentage achieved in other studies in non-criti-
cally ill hospitalised patients not receiving enteral
nutrition.80 It must be considered that it is not
uncommon for enteral nutrition to be unexpectedly
suspended (due to gastrointestinal complications, diag-
nostic test requirements, accidental feeding tube
removal, drug administration, etc.). 
The lack of prospective randomised studies involving
an adequate number of patients encourages guidelines,
reviews and consensuses to make recommendations
based not on evidence but on the experience of the
different groups.5,17,75,81
Therefore, some authors suggest that the administra-
tion of lower but more frequent doses of intermediate-
acting insulins (NPH, NPL or similar) or regular
insulin could reduce the risk of hypoglycaemia and
insulin-associated risks and, moreover, reduce the
number of injections and controls. Furthermore, inter-
mediate-acting insulins could be more useful when
adjusting the dose of enteral nutrition received (since
its half-life is shorter), adding regular insulin or rapid-
acting insulin analogs as needed.5,75,77 They could also
be used in patients receiving night-time EN infusions
in one or two doses. Long-acting insulins (insulin
glargine or two doses of insulin detemir) would be
reserved for patients with more stable requirements or
receiving EN infusion as boluses combined with ultra-
fast-acting insulin.5,17,75 Nevertheless, all imaginable
options are possible, especially if the theoretical insulin
action is adapted to the enteral nutrition infusion
regimen (continuous, bolus, cyclic, nocturnal, etc.).5
Treatment of hyperglycaemia in non-critically 
ill patients receiving TPN 
The current discussion in literature regarding inten-
sive treatment with insulin therapy in critically ill
patients has been mentioned above. In most of these
studies, parenteral nutrition and/or glucose solution
infusions are combined with enteral nutrition adminis-
tering insulin by way of perfusion pumps that are sepa-
rate from the TPN. However, outside the intensive care
units (where the health professional-to-patient ratio is
high) or outside the context of clinical trials, the use of
protocols for intravenous insulin therapy with separate
nutrition infusion is less common, except in cases with
very poor metabolic control.
In 2006, a group of hospital pharmacists in Spain
reported that up to 18% of patients with TPN and
hyperglycaemia with blood sugar levels above 200
mg/dl were not receiving any insulin treatment and
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almost 57% were only receiving such treatment via
subcutaneous injection.39
However, more recently, in 605 non-critically ill
patients receiving TPN under the care of endocrinolo-
gists in the Nutrition Units, 71.1% of the cases evalu-
ated were prescribed insulin, with 58.1% of the patients
with no glucose metabolism alteration also receiving
insulin. In this study, of all the cases treated with
insulin (n = 433), intravenous insulin was used in 55%
of the cases, added to the TPN bag (36%) or by intra-
venous perfusion (8.8%). Subcutaneous administration
alone was used in 55.1 % of cases.82
The use of insulin added to the TPN bag, with adjust-
ments of subcutaneous regular insulin every 6-8 hours
(or rapid-acting insulin analogs every 4 to 6 hours), is a
common practice in Spain and other countries that
often allows reasonable metabolic control to be
achieved in patients.5,38,75,81,83 Nevertheless, there are no
randomised studies comparing the efficacy and effec-
tiveness of different insulin therapy regimens in TPN.83
Although adsorption to the bags is a controversial
subject,84,85 the percentage lost seems to be minimal in
ternary mixtures using the new bags. To adjust the
insulin therapy, one-half to two-thirds of the subcuta-
neous units administered the previous day are added to
the bag. The mean doses used in patients with known
diabetes generally reach 0.7-0.8 IU/kg of bodyweight
or 0.3 IU/gram of infused carbohydrate.38,82 In patients
with stress hyperglycaemia, the usual doses range
between 0.1 and 0.15 IU per gram of carbohydrate
infused via TPN. With this regimen, the risk of hypo-
glycaemia is low since the insulin perfusion is discon-
tinued with TPN withdrawal. 
There are other specific protocols for managing
insulin in TPN that have been recently proposed, such
as adding regular insulin (2/3 of the calculated dose) to
the bag with NPH insulin every 6-8 hours (a total of 1
unit every 5 to 20 grams of carbohydrate based on
whether diabetes was previously diagnosed or not and
the blood glucose levels at the start) and “basal” insulin
in diabetics or corticosteroids at doses of 0.15 to 0.25
IU/kg administered as NPH insulin every 6 to 8 hours.
This regimen could be more effective than ad hoc regi-
mens in which insulin was added on demand.86 Satis-
factory results have also been published in short studies
or isolated clinical cases with other slow-acting
insulins such as insulin glargine or NPL78,87.
.
When it is
not possible to control hyperglycaemia, the infusion of
IV insulin separately from TPN may be necessary.5
On the other hand, as was mentioned earlier on, it is
fundamental to adequately calculate requirements, not to
administer high doses of glucose and to take into account
all nutrients supplied (not just from TPN but also
including dextrose/glucosaline solutions) in order to
prevent and treat TPN-associated hyperglycaemia83,88-90 as
hyperglycaemia and complications would be affected by
the total amount of glucose and calories infused.49,91
In the case of type 1 diabetes, some authors suggest
administering low doses of insulin detemir or glargine
to prevent ketoacidosis if TPN is suddenly discon-
tinued.17
.
Although the use of special amino acid (e.g. enriched
with glutamine)92-94 or lipid formulas (based on olive oil
or supplemented with omega-3 fatty acids)83 may be
beneficial to prevent or treat hyperglycaemia, there is
not sufficient data in the literature to make recommen-
dations. 
Conclusions of the Garin Group 
After systematically reading the literature and in
view of the lack of studies allowing recommendations
based upon high-level evidence to be reached
regarding the best strategy for preventing and treating
patients with diabetes and hyperglycaemia and artifi-
cial nutrition, we hereby make the following recom-
mendations based on data from the literature and the
group’s clinical experience. 
Question 1: Is hyperglycaemia and the presence 
of diabetes a major problem in patients receiving 
artificial nutrition?
1. Hyperglycaemia in patients receiving enteral or
parenteral nutrition is a major problem in both hospi-
talised patients and outpatients due to its high preva-
lence and possible consequences in terms of morbidity
and mortality, regardless of the pre-existence of
glucose metabolism disorders. 
2. It is recommended that these patients be moni-
tored by nutritional support teams with specific
training in clinical nutrition and diabetology given that
it is common that specific hypoglycaemic treatments
which can determine the effectiveness of parenteral
and enteral artificial nutrition are used. 
Question 2: Are the indications for artificial 
nutrition different in patients with diabetes 
or hyperglycaemia vs. non-diabetics?
3. The indications and access routes for artificial
nutrition are no different in patients with diabetes or
stress hyperglycaemia than in non-diabetics. As an
exception, in the case of diabetic gastroparesis requiring
EN, post-pyloric (non-gastric) enteral access place-
ment is recommended. 
Question 3: What is the definition of stress 
hyperglycaemia and “at risk for the development 
of diabetes”? 
4. In hospitalised patients with unknown diabetes
and in the context of an acute disease, stress hypergly-
caemia is defined as plasma glucose levels above 126
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mg/dl in fasting conditions or above 200 mg/dl at any
time with glycated haemoglobin levels below 5.7%. By
definition, this increase would be transient (it disap-
pears once the disease causing admission is resolved)
then we recommend reassessing metabolic state three
months after reaching clinical stability by doing blood
glucose and HbA1C tests. 
5. We propose defining hospitalised patients as
being “at risk for the development of diabetes” prior to
admission when said patients have unknown diabetes
and, in the context of an acute disease, have plasma
glucose levels above 126 mg/dl in fasting conditions or
above 200 mg/dl at any time with glycated haemo-
globin levels between 5.7% and 6.5% as having pre-
admission glucose metabolism alteration. We recom-
mend reassessing metabolic state three months after
reaching clinical stability by performing blood glucose
and HbA1C tests.
6. To define both stress hyperglycaemia and being
pre-admission “at risk for the development of diabetes”,
it would be necessary to measure HbA1C in all hospi-
talised patients with hyperglycaemia (above 126
mg/dl) in order to correctly classify the condition and
determine the best possible hypoglycaemic treatment
during admission and upon discharge (table I).
Question 4: Are there any proven benefits 
from strictly controlling blood glucose 
levels in patients receiving artificial nutrition 
and what would be the objectives of such 
controls in non-critically ill patients?
7. Strict blood glucose level control (80-110 mg/dl)
is not recommended for ICU patients or non-critically
ill patients receiving artificial nutrition. The objectives
of metabolic control (during admission), if receiving
continuous nutrient infusion, must be to keep blood
glucose levels between 140 and 180 mg/dl. In patients
receiving discontinuous artificial feeding infusion, the
objective must be to keep pre-prandial blood glucose
levels between 100 and 140 mg/dl and post-prandial
levels between 140 and 180 mg/dl. It is necessary to
inform the patient of the importance of taking a series
of blood glucose measurements and of starting drug
treatment if these limits are exceeded. Insulin therapy
must be started in patients with blood glucose levels
above 180 mg/dl. We also recommend starting insulin
therapy at levels above 140 mg/dl, although therapy
can be personalised based on the patient’s individual
characteristics (risk of hypoglycaemia). 
Question 5: Can hyperglycaemia be prevented 
in patients receiving artificial nutrition?
8. It is recommended that all patients starting artificial
nutrition (enteral and/or parenteral), with or without a
history of diabetes, have their blood glucose levels moni-
tored initially every 6-8 hours and for at least 24 hours
after reaching the total estimated requirements. After
this, if blood glucose levels are below 140 mg/dl, the
number of controls may be decreased based on the
patient’s clinical condition (table II).
9. Hyperglycaemia can be prevented in patients
receiving artificial nutrition by implementing local
protocols that adequately calculate energy-protein
needs. It is vital to provide individualised nutritional
requirements based on the patient’s clinical condition,
body composition, age and gender. This implies not
giving excess calories to a population that often suffers
from obesity. We therefore recommend calculating
baseline requirements by applying the Harris-Benedict
formula as this includes age as a variable. To calculate
the total requirements, we recommend multiplying the
baseline energy expenditure (Harris-Benedict) by a
stress factor of between 1.1 and 1.3, depending on the
condition indicating the use of artificial nutrition
(greater requirements are only needed in exceptional
cases). We recommend using the real weight in
malnourished and normally nourished patients (up to a
BMI of 25 kg/m2) for calculations. Above this limit we
recommend using the adjusted weight, taking the
weight that would give a BMI of 24 kg/m2. 
10. In all patients receiving artificial nutrition, espe-
cially those receiving parenteral nutrition, it is neces-
sary to take into account all glucose administered
(including glucose drips) to prevent the deleterious
effects of hyperglycaemia.
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Table I
Definition proposed for stress hyperglycaemia
and “at risk for the development of diabetes”
prior to admission
Stress hyperglycaemia “At risk for the development
of diabetes” prior to admission
Blood glucose levels ≥ = 126 mg/dl in fasting conditions 
or ≥ 200 mg/dl at any time
No known diabetes, in context of hospital admission for acute disease
HbA1C < 5.7% HbA1C ≥ 5.7 and < 6.5%
Reassess after 3 months with blood glucose and HbA1C tests
Table II
Strategies to prevent to hyperglycaemia
during artificial nutrition
Monitor capillary blood glucose levels every 6-8 hours when starting
artificial nutrition
Strict calculation of energy needs
– Hospitalised patients. Harris-Benedict formula * Stress factor 
(1.1-1.3). Use adjusted bodyweight in patients with BMI > 25 kg/m2
– Outpatients. Harris-Benedict formula * Physical activity factor, or
equations proposed by US National Academy of Sciences.
Take into account all glucose supplies
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11. In the case of outpatients, to calculate total
energy expenditure we recommend applying the Harris-
Benedict formula and multiplying by a coefficient that
takes into account physical activity or using the equa-
tions proposed by the US National Academy of Sciences
(which already include physical activity).95,96
12. The estimated protein requirement, in the absence
of limiting renal or hepatic disease, will depend on the
degree of metabolic stress shown by the patient. General
estimates are 1 g/kg/day (in patients with no or minimum
stress) and 1.5 g/kg/day (in patients with severe stress),
which may be increased in exceptional cases with large
additional losses (e.g. large burn areas). 
Question 6: In the field of enteral nutrition 
and hyperglycaemia and diabetes, should 
diets designed for patients with diabetes be used 
in the presence of stress hyperglycaemia/
diabetes? What would be the recommended 
macronutrient composition?
13. In patients with enteral nutrition and stress
diabetes, we recommend using diets designed for
patients with diabetes and stress hyperglycaemia with a
high or moderate monounsaturated fat content to facili-
tate metabolic control and achieve therapeutic objec-
tives as these formulas have proven to reduce post-pran-
dial blood glucose levels, insulin requirements and, in
some papers, glycaemic variability and medium-term
HbA1C without worsening or maybe even improving
the lipid profile. However, there is no evidence of
improvement in morbidity and mortality. We recom-
mend initially avoiding these diets in patients with
gastroparesis if enteral nutrition is given via the gastric
route. We recommend high-monounsaturated fat
formulas that give between 38 and 52% of lipids plus
fibre (high proportion of fermentable/soluble fibre) and
low glycaemic index/load carbohydrates. 
14. In the presence of other underlying concomitant
conditions requiring treatment with enteral nutrition
and specific formulas (e.g. renal failure, liver failure),
treatment according to the main condition will prevail.
Choosing between the different preparations will
therefore also depend on the clinical situation of the
patient in question (presence of malabsorption, severe
renal, liver or lung failure, presence of diabetic gastro-
paresis, site of formula infusion, special requirements,
restriction of certain nutrients or volume, etc.). In these
cases, compliance with therapeutic objectives will
basically depend on the insulin therapy prescribed. 
Question 7: What is the best drug treatment 
for treating hyperglycaemia/diabetes 
in hospitalised patients and outpatients?
15. In hospitalised patients with stress hypergly-
caemia or diabetes, the best treatment is insulin therapy.
16. For outpatients, drug treatment will follow the
same recommendations and clinical practice guide-
lines as all other general patients (with both insulin and
oral anti-diabetic drugs being used).
Question 8: What is the best insulin therapy 
regimen in hospitalised patients and outpatients 
receiving enteral nutrition?
17. It is not known which is the best insulin therapy
regimen in hospitalised patients or outpatients receiving
artificial nutrition. We recommend (table III): 
a) Basal-bolus regimens in patients receiving enteral
nutrition by bolus feeding or gravity. Total initial
requirements will depend on previous treatments.
a) a) If treated previously with oral anti-diabetic
drugs, we recommend estimating the total
initial insulin dose between 0.3 and 0.5 U/kg
of adjusted bodyweight/day (based on BMI,
home treatment, intercurrent processes,
admission blood glucose levels and/or corti-
costeroid prescription).
a) b) If treated previously with insulin therapy, the
dose will be personalised based on previous
doses and clinical condition. 
a) c) In general, doses with 40% of total insulin as
basal insulin and 60% as prandial insulin will
be applied (to prevent hypoglycaemia if enteral
nutrition is suddenly discontinued). Prandial
insulin injections will preferably be ultra-rapid-
acting insulin (aspart, lispro or glulisine)
injected just before starting the infusion or after
completing infusion (if there is a risk of intoler-
ance to prevent hypoglycaemia). The prandial
dose will depend on the amount of carbohy-
drates infused and adjustment based on blood
glucose levels prior to infusion. 
a) d) When starting enteral nutrition or in unstable
patients (requiring frequent dose adjustments),
we recommend covering baseline requirements
with NPH, NPL or detemir. In stable patients or
patients receiving enteral nutrition at final
doses, insulin glargine may also be used.
b) In patients receiving continuous enteral nutrition,
we recommend a baseline insulin regimen of 40%
basal insulin and 60% prandial insulin preferably
every 8 hours with rapid-acting insulin (regular) as
nutritional insulin in three equal parts (every 8
hours) + adjustment regimen (based on pre-injec-
tion blood glucose levels). Basal insulin may be
insulin glargine once a day, detemir twice a day,
NPH or NPL 2-3 times a day or NPH or NPL
insulin mix two or three times a day. Dose calcula-
tion will be similar to that described above.
c) In patients receiving cyclic (e.g. night-time)
feeding, we recommend using a medium-acting
basal insulin (NPH, NPL or Detemir) injected a
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half hour to an hour before starting infusion +
adjustments, if required, with regular or ultra-
rapid-acting insulin on starting the infusion and
every 4-8 hours according to controls. 
Question 9: In the field of parenteral nutrition 
and hyperglycaemia and diabetes, what proportion 
of macronutrients would be best?
18. There are no specific studies regarding the best
proportion of macronutrients to prevent hyperglycaemia in
patients with diabetes or stress hyperglycaemia. However,
if total requirements are estimated according to the recom-
mendations given above, the proportion of carbohydrates
and lipids for infusion will be adequate. After estimating
total calories, we recommend calculating amino acid
requirements and subtracting the resulting calories from
the total. The remaining calories (non-protein) will then be
divided between carbohydrates and lipids in percentages
that may range between 60% carbohydrates and 40% lipids
to a maximum of 60% lipids and 40% carbohydrates (if
there is a greater risk of hyperglycaemia or hyperglycaemia
cannot be controlled). Either way, this calculation proce-
dure entails infusing 2-4 grams/kg of bodyweight/day of
carbohydrates and 1-1.3 g/kg of bodyweight/day of lipids
(we recommend not exceeding 1.5 grams of lipids per
kg/day, especially in severely ill patients). 
Question 10: In the field of parenteral nutrition 
and hyperglycaemia and diabetes, what type 
of macro- and micronutrients would be best?
19. There are no data in the literature specifically
evaluating these aspects. However, based on phys-
iopathological studies, the use of glutamine or lipids
based on olive oil or supplemented with omega-3 fatty
acids in patients with increasing metabolic stress could
be a reasonable option. 
Question 11: What is the best insulin therapy 
regimen in non-critically ill hospitalised patients 
with diabetes/hyperglycaemia receiving TPN? 
20. We recommend adding regular insulin to TPN
bags with a subcutaneous regular (not rapid-acting
insulin analogs) insulin regimen every 6-8 hours based
on capillary blood glucose levels, with adjustments
above 140 mg/dl. In all cases, if the therapeutic objec-
tives are not achieved, the equivalent of 2/3 of the
subcutaneous rescue insulin dose required the previous
day will be added daily to the bag (table IV). We have
applied the following assumptions:
a) No known diabetes and blood glucose levels
prior to starting the TPN infusion above 140
mg/dl or no clinical condition commonly associ-
ated with hyperglycaemia (severe acute pancre-
atitis, concomitant use of corticosteroids): start
with 1 IU/10 g of glucose in the TPN. Alterna-
tive: start with 0.25 IU/kg of adjusted body-
weight. 
b) Known diabetes without insulin therapy: start
with 1 IU (low stress) to 2 IU (high stress or corti-
costeroids) for every 10 g of glucose in the TPN. 
c) Known diabetes undergoing home treatment with
insulin: start with 2 IU per 10 g of glucose or 0.5
IU/kg of bodyweight. As an alternative, start with
half (if low stress) to 2/3 (if high stress) of
previous outpatient requirements in the bag. 
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Table III
Approach to insulin therapy in control nutrition (EN)
Basal Prandial Adjustment regimen
40% 60% Based on capillary blood glucose
Continous EN Glargine (one a day) Every 8 hours levelsDetemir (twice a day) In 3 equal parts Same insulin as prandialNPH, NPL (2-3 times a day) 1st option: Regular insulin
40% 60%
When starting EN or stable Rapid-acting insulin analogs Same insulin as prandial (base
Bolus or gravity EN patients ➔NPH, NPL or detemir (lispro, aspart, glulisine) on capillary blood glucose levels
Stable patients or patients receiving according to amount of prior to infusion)
EN at final dose ➔ can also use glargine   carbohydrates infused
At the start and every 4-8 hours 
Medium-acting insulin (NPH, NPL or detemir) 30-60 minutes according to capillary blood glucoseCyclic EN before infusion levelsRegular or rapid-acting insulin 
analogs
Calculation of total initial insulin requirements. According to previous treatment:
With oral anti-diabetic drugs: 0.3-0.5 U/kg adjusted bodyweight/day (based on BMN, home treatment, admission blood glucose levels, intercurrent 
processes, corticosteroids).
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21. In patients with type 1 diabetes, in addition to
the insulin placed in the bag and the adjustment
regimen, we recommend injecting between 0.05 and
0.1 IU/kg of subcutaneous basal insulin (to prevent
ketoacidosis if the TPN infusion is suddenly discon-
tinued). We recommend a preferable use of insulin
glargine (once a day) or detemir (once or twice a day)
in these cases. 
22. In patients receiving home parenteral nutrition
and cyclic infusion, subcutaneous insulin may achieve
reasonable control of TPN-associated hyperglycaemia
in non-diabetic patients. We recommend a dose of
detemir prior to infusion. 
23. If metabolic objectives are not achieved with the
usual regimen, continuous insulin infusion using sepa-
rate infusion pumps from TPN would be proposed. 
Question 12: What would your future investigation
recommendations be in the field of diabetes/
hyperglycaemia and artificial nutrition?
24. It is necessary to expand on studies assessing
the prevalence of glucose metabolism alterations
(diabetes and stress hyperglycaemia) in patients
receiving both parenteral and enteral artificial nutrition
(in different clinical situations, both hospitalised and as
outpatients).
25. It is necessary to assess the physiopathological
determining factors of stress hyperglycaemia and, at a
clinical level, the natural history of this condition, with
it being necessary to reassess the persistence of long-
term glucose metabolism alterations after acute
processes in order to reclassify patients. Considering
these data, a consensus should be reached regarding
diagnostic criteria for stress hyperglycaemia and other
glucose metabolism alterations. 
26. More studies are required in non-critically ill
hospitalised patients in order to define glycaemic
control objectives by evaluating morbidity, mortality
and efficiency criteria. 
27. Prospective clinical studies must be conducted to
compare the use of different enteral nutrition formulas in
patients with diabetes and/or stress hyperglycaemia.
These must include more patients, lower protocol with-
drawal rates, longer duration (especially in outpatients),
be randomised and preferably double-blind in different
clinical situations and should assess the efficacy and effi-
ciency (cost/effectiveness) of such formulas on meta-
bolic effect and morbidity/mortality in order to be able to
make evidence-based recommendations.
28. It is necessary to conduct clinical trials
comparing different insulin therapy regimens in both
enteral and parenteral nutrition and different clinical
scenarios, assessing not only metabolic control para-
meters but also their effect on morbidity and mortality. 
29. Studies assessing the role of other aspects of the
treatment of patients receiving artificial nutrition with
hyperglycaemia should be conducted (such as the addi-
tion of micronutrients, drug nutrients, glutamine, whey
proteins, omega-3 fatty acids, etc.). 
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Table IV
Approach to insulin therapy in parenteral nutrition
Parenteral nutrition in hospitalised patients: 
– Add regular insulin to TPN bags in combination with subcutaneous regular (not rapid-acting insulin analogs) insulin regimen
every 6-8 hours based on capillary blood glucose levels, with adjustments above 140 mg/dl.
– Add the equivalent of 2/3 of subcutaneous rescue insulin dose required the previous day every day
– In cases of uncontrolled hyperglycaemia, separate intravenous insulin infusions from TPN may be required.
Recommended initial insulin dose:
– Unknown diabetes and prior blood glucose levels > 140 mg/dl or no clinical condition commonly associated with hyperglycae-
mia (severe acute pancreatitis, corticosteroids):  start with 1 IU/10 g glucose in TPN, or start with 0.25 IU/ kg adjusted body-
weight.
– Known diabetes without insulin therapy: start with 1 IU (low stress) to 2 IU (high stress or corticosteroids) for every 10 g glu-
cose in TPN.
– Known diabetes receiving home insulin therapy: start with 2 IU/10 g glucose or 0.5 IU/kg of bodyweight, or start with 50-66%
of previous outpatient requirements in bag.
In patients with type 1 diabetes, in addition to insulin placed in bag and adjustment regimen, inject 0.05-0.1 IU/kg bodyweight of
subcutaneous basal insulin.
Home parenteral nutrition and cyclic infusion: Medium-acting basal insulin (detemir or similar) prior to infusion. Add adjust-
ment regimen if required. 
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